Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Advances in Therapy
Published in: Advances in Therapy 12/2020

Open Access 01-12-2020 | Migraine | Review

Evaluation of Patients with Insufficient Efficacy and/or Tolerability to Triptans for the Acute Treatment of Migraine: A Systematic Literature Review

Authors: Elizabeth Leroux, Andrew Buchanan, Louise Lombard, Li Shen Loo, Daisy Bridge, Ben Rousseau, Natasha Hopwood, Brandy R. Matthews, Uwe Reuter

Published in: Advances in Therapy | Issue 12/2020

Login to get access

Abstract

Introduction

Use of triptans for acute treatment of migraine is associated with insufficient efficacy and/or tolerability in approximately 30–40% of people. We conducted a systematic literature review (SLR) to synthesize definitions, terminology, subsequent treatment outcomes, and characteristics associated with this subpopulation.

Methods

A comprehensive SLR was conducted to identify studies, published from Jan 1995 to May 2019, which focused on insufficient efficacy and/or tolerability to triptans.

Results

Thirty-five publications were identified, of which 22 described randomized controlled trials and open-label studies, and 13 described observational studies. Across studies, multiple objectives and a high amount of variability in methodologies and outcomes were noted. The most commonly applied measures of efficacy were headache pain freedom and pain relief at 2 h. Ten studies assessed efficacy of switching or optimizing treatment in patients with historical insufficient efficacy or tolerability to previous triptan treatment and demonstrated varying levels of success. Factors associated with increased risk of triptan insufficient efficacy included severe baseline headache severity, photophobia, phonophobia, nausea, and depression.

Conclusions

Irrespective of the methodology or definition used to identify people with insufficient efficacy and/or tolerability to triptans, study results support the assertion that a high unmet need remains for effective acute treatment of migraine.
Appendix
Available only for authorised users
Literature
1.
American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache. 2019;59(1):1–18.
2.
Bartsch T, Knight YE, Goadsby PJ. Activation of 5-HT(1B/1D) receptor in the periaqueductal gray inhibits nociception. Ann Neurol. 2004;56(3):371–81.
3.
Tepper SJ, Rapoport AM, Sheftell FD. Mechanisms of action of the 5-HT1B/1D receptor agonists. Arch Neurol. 2002;59(7):1084–8.
4.
Xia Y, Kelton CM, Wigle PR, Heaton PC, Guo JJ. Twenty years of triptans in the United States Medicaid programs: utilization and reimbursement trends from 1993 to 2013. Cephalalgia. 2016;36(14):1305–15.
5.
Tfelt-Hansen P, Steiner TJ. Over-the-counter triptans for migraine: what are the implications? CNS Drugs. 2007;21(11):877–83.
6.
Frisk P, Sporrong SK, Ljunggren G, Wettermark B, von Euler M. Utilisation of prescription and over-the-counter triptans: a cross-sectional study in Stockholm, Sweden. Eur J Clin Pharmacol. 2016;72(6):747–54.
7.
Parkinson B, Gumbie M, Cutler H, Gauld N, Mumford V, Haywood P. Cost-effectiveness of reclassifying triptans in Australia: application of an economic evaluation approach to regulatory decisions. Value Health. 2019;22(3):293–302.
8.
Viana M, Genazzani AA, Terrazzino S, Nappi G, Goadsby PJ. Triptan nonresponders: do they exist and who are they? Cephalalgia. 2013;33(11):891–6.
9.
Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002;22(8):633–58.
10.
Lipton RB, Buse DC, Serrano D, Holland S, Reed ML. Examination of unmet treatment needs among persons with episodic migraine: results of the American Migraine Prevalence and Prevention (AMPP) Study. Headache. 2013;53(8):1300–11.
11.
Lipton RB, Hamelsky SW, Dayno JM. What do patients with migraine want from acute migraine treatment? Headache. 2002;42(Suppl 1):3–9.
12.
Dodick DW. Triptan nonresponder studies: implications for clinical practice. Headache. 2005;45(2):156–62.
13.
Messali AJ, Yang M, Gillard P, et al. Treatment persistence and switching in triptan users: a systematic literature review. Headache. 2014;54(7):1120–30.
14.
Cameron C, Kelly S, Hsieh SC, et al. Triptans in the acute treatment of migraine: a systematic review and network meta-analysis. Headache. 2015;55(Suppl 4):221–35.
15.
16.
17.
18.
19.
Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
20.
Seeburger JL, Taylor FR, Friedman D, et al. Efficacy and tolerability of rizatriptan for the treatment of acute migraine in sumatriptan non-responders. Cephalalgia. 2011;31(7):786–96.
21.
Diener HC. Efficacy of almotriptan 12.5 mg in achieving migraine-related composite endpoints: a double-blind, randomized, placebo-controlled study in patients controlled study in patients with previous poor response to sumatriptan 50 mg. Curr Med Res Opin. 2005;21(10):1603–10.
22.
Farkkila M, Olesen J, Dahlof C, et al. Eletriptan for the treatment of migraine in patients with previous poor response or tolerance to oral sumatriptan. Cephalalgia. 2003;23(6):463–71.
23.
Stark S, Spierings EL, McNeal S, Putnam GP, Bolden-Watson CP, O’Quinn S. Naratriptan efficacy in migraineurs who respond poorly to oral sumatriptan. Headache. 2000;40(7):513–20.
24.
Landy S, McGinnis J. Early migraine intervention with sumatriptan 100 mg in patients with a history of nonresponse to sumatriptan 50 mg: an open-label, prospective study of multiple attacks. Curr Ther Res Clin Exp. 2004;65(4):353–9.
25.
Mathew NT, Kailasam J, Gentry P, Chernyshev O. Treatment of nonresponders to oral sumatriptan with zolmitriptan and rizatriptan: a comparative open trial. Headache. 2000;40(6):464–5.
26.
Newman LC, Cady RK, Landy S, et al. Treatment satisfaction and efficacy of the rapid release formulation of sumatriptan 100 mg tablets utilising an early intervention paradigm in patients previously unsatisfied with sumatriptan. Int J Clin Pract. 2008;62(12):1889–99.
27.
Goldstein J, Tiseo PT, Albert KS, Li C, Sikes CR. Eletriptan in migraine patients reporting unsatisfactory response to rizatriptan. Headache. 2006;46(7):1142–50.
28.
Diamond S, Freitag FG, Feoktistov A, Nissan G. Sumatriptan 6 mg subcutaneous as an effective migraine treatment in patients with cutaneous allodynia who historically fail to respond to oral triptans. J Headache Pain. 2007;8(1):13–8.
29.
Mathew NT, Landy S, Stark S, et al. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. Headache. 2009;49(7):971–82.
30.
Färkkilä M, Diener H-C, Géraud G, et al. Efficacy and tolerability of lasmiditan, an oral 5-HT1F receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol. 2012;11(5):405–13.
31.
Ho TW, Olesen J, Dodick DW, Kost J, Lines C, Ferrari MD. Antimigraine efficacy of telcagepant based on patient’s historical triptan response. Headache. 2011;51(1):64–72.
32.
Blumenfeld AM, Goadsby PJ, Dodick DW, et al. Ubrogepant is effective for the acute treatment of migraine in patients with an insufficient response to triptans (P3.10-024). Neurology. 2019;92(15 Suppl):P3.10-024.
33.
Knievel KLL, Buchanan A, et al. Response to lasmiditan for acute treatment of migraine based on prior response to triptan therapy. 12th European Headache Federation Congress jointly with 32nd National Congress of the Italian Society for the Study of Headaches, Florence, Italy. 28–30 September 2018. J Headache Pain. 2018;19(Suppl 1):32–3.
34.
Tietjen GE, Athanas K, Utley C, Herial NA, Khuder SA. The combination of naratriptan and prochlorperazine in migraine treatment. Headache. 2005;45(6):751–3.
35.
Cady R, Martin V, Mauskop A, et al. Symptoms of cutaneous sensitivity pre-treatment and post-treatment: results from the rizatriptan TAME studies. Cephalalgia. 2007;27(9):1055–60.
36.
Munjal S, Reed ML, Buse DC, Bennett A, Fanning KM, Lipton RB. The impact of triptan use and allodynia on initial and sustained response to medication in episodic migraine (EM): results from American migraine prevalence and prevention study (AMPP). In: Abstracts from the 58th Annual Scientific Meeting, AHS (June 9–16, 2016), 2016; PF04.2016; 56(S1):3–83.
37.
Silberstein SD, Shewale AR, Baradaran S, et al. Opioid use, rebound headache, and resource utilization among migraine patients with insufficient response to triptans based on real-world data (S59.007). Neurology. 2019;92(15 Suppl):S59.007.
38.
Sarchielli P, Pini LA, Zanchin G, et al. Clinical-biochemical correlates of migraine attacks in rizatriptan responders and non-responders. Cephalalgia. 2006;26(3):257–65.
39.
Patrick DL, Hurst BC, Hughes J. Further development and testing of the migraine-specific quality of life (MSQOL) measure. Headache. 2000;40(7):550–60.
40.
Peng K, Fuh J, Wang S. The effectiveness and adverse events of sumatriptan: who are susceptible? In: Abstracts from the 58th Annual Scientific Meeting, AHS (June 9–16, 2016), 2016; PF04.2016; 56(S1):3–83.
41.
Seo JG, Park SP. Factors associated with frovatriptan response in patients with migraine: a prospective, observational study. Cephalalgia. 2016;36(5):493–8.
42.
Sheftell F, Almas M, Weeks R, Mathew NT, Pitman V, Lipton RB. Quantifying the return of headache in triptan-treated migraineurs: an observational study. Cephalalgia. 2010;30(7):838–46.
43.
Terrazzino S, Viana M, Floriddia E, et al. The serotonin transporter gene polymorphism STin2 VNTR confers an increased risk of inconsistent response to triptans in migraine patients. Eur J Pharmacol. 2010;641(2–3):82–7.
44.
Wang S-J, Peng K-P, Fuh J-L, Chen S-P, Wang Y-F. Sumatriptan response and predictors in migraine patients: a large clinic-based cohort study. Cephalalgia. 2017;37(1_suppl):25–51.
45.
Diener HC, Dodick DW, Goadsby PJ, Lipton RB, Almas M, Parsons B. Identification of negative predictors of pain-free response to triptans: analysis of the eletriptan database. Cephalalgia. 2008;28(1):35–40.
46.
Lombard L, Schroeder K, Nichols R, Kar-Chan Choong C, Ye W. Characteristics, treatment patterns, and healthcare resource utilization in patients with migraine who initiated a triptan. Headache. 2018;58(S2):182–183 [PS54].
47.
Diener H-C, Holle-Lee D, Nägel S, et al. Treatment of migraine attacks and prevention of migraine: guidelines by the German Migraine and Headache Society and the German Society of Neurology. Clin Transl Neurosci. 2019;3(1):2514183X18823377.
48.
Lanteri-Minet M, Valade D, Geraud G, Lucas C, Donnet A. Revised French guidelines for the diagnosis and management of migraine in adults and children. J Headache Pain. 2014;5:2.
49.
50.
Worthington I, Pringsheim T, Gawel MJ, et al. Canadian Headache Society Guideline: acute drug therapy for migraine headache. Can J Neurol Sci. 2013;40(5 Suppl 3):S1–80.
51.
Steiner TJ, Jensen R, Katsarava Z, Linde M. Aids to management of headache disorders in primary care (2nd edition): on behalf of the European Headache Federation and Lifting The Burden: the Global Campaign against Headache. J Headache Pain. 2019;20(1):57.
52.
Christoph-Diener H, Ferrari M, Mansbach H, SNAP Database Study Group. Predicting the response to sumatriptan: the Sumatriptan Naratriptan Aggregate Patient Database. Neurology. 2004;63(3):520–4.
53.
Newman LC. Why triptan treatment can fail: focus on gastrointestinal manifestations of migraine. Headache. 2013;53(Suppl 1):11–6.
54.
Maasumi K, Tepper SJ, Kriegler JS. Menstrual migraine and treatment options: review. Headache. 2017;57(2):194–208.
55.
Lombard L, Farrar M, Ye W, et al. A global real-world assessment of the impact on health-related quality of life and work productivity of migraine in patients with insufficient versus good response to triptan medication. J Headache Pain. 2020;21(1):41.
56.
Zebenholzer K, Gall W, Wöber C. Use and overuse of triptans in Austria—a survey based on nationwide healthcare claims data. J Headache Pain. 2018;19(1):34.
57.
Piccinni C, Cevoli S, Ronconi G, et al. A real-world study on unmet medical needs in triptan-treated migraine: prevalence, preventive therapies and triptan use modification from a large Italian population along two years. J Headache Pain. 2019;20(1):74.
58.
Hansen TF, Chalmer MA, Haspang TM, Kogelman L, Olesen J. Predicting treatment response using pharmacy register in migraine. J Headache Pain. 2019;20(1):31.
59.
van Hoogstraten WS, Van Den Brink AM. The need for new acutely acting antimigraine drugs: moving safely outside acute medication overuse. J Headache Pain. 2019;20(1):54.
60.
Knievel K, Buchanan AS, Lombard L, et al. Lasmiditan for the acute treatment of migraine: subgroup analyses by prior response to triptans. Cephalalgia. 2020;40(1):19–27.
61.
Ferrari A, Tiraferri I, Neri L, Sternieri E. Why pharmacokinetic differences among oral triptans have little clinical importance: a comment. J Headache Pain. 2011;12(1):5–12.
62.
Goadsby PJ, Zanchin G, Geraud G, et al. Early vs. non-early intervention in acute migraine-‘Act when Mild (AwM)’. A double-blind, placebo-controlled trial of almotriptan. Cephalalgia. 2008;28(4):383–91.
63.
Brandes JL, Poole A, Kallela M, et al. Short-term frovatriptan for the prevention of difficult-to-treat menstrual migraine attacks. Cephalalgia. 2009;29(11):1133–48.
64.
Scott RJ, Aitchison WR, Barker PR, McLaren GI. Oral sumatriptan in the acute treatment of migraine and migraine recurrence in general practice. QJM. 1996;89(8):613–22.
65.
66.
Landy SH, Tepper SJ, Schweizer E, Almas M, Ramos E. Outcome for headache and pain-free nonresponders to treatment of the first attack: a pooled post hoc analysis of four randomized trials of eletriptan 40 mg. Cephalalgia. 2014;34(5):376–81.
67.
Spierings EL, Keywood C. Rapid responders to frovatriptan in acute migraine treatment: results from a long-term, open-label study. Pain Med. 2009;10(4):633–8.
68.
Sheftell FD, Feleppa M, Tepper SJ, Volcy M, Rapoport AM, Bigal ME. Patterns of use of triptans and reasons for switching them in a tertiary care migraine population. Headache. 2004;44(7):661–8.
69.
al Deeb S, al Kawi Z, Yaqub B, Bohlega S, Cheung P. Sumatriptan treatment of acute migraine attacks in a Saudi population. Clin Neurol Neurosurg. 1997;99(1):23–5.
70.
Miljkovic S, Smajlovic D, Crncevic S, et al. Efficient therapy for treatment of migraine without aura: ergotamine based drugs or sumatriptan. 12th European Headache Federation Congress jointly with 32nd National Congress of the Italian Society for the Study of Headaches. J Headache Pain. 2018;19(1):80.
71.
Linder, S.L. Subcutaneous sumatriptan in the clinical setting: the first 50 consecutive patients with acute migraine in a pediatric neurology office practice. Headache J Head Face Pain 1996;36:419–22.
72.
Alam A, Munjal S, Reed ML. Triptan use and discontinuation in a representative sample of persons with migraine: results from Migraine in America symptoms and treatment (mast) study. Presented at 60th Annual Scientific Meeting American Headache Society® June 28‐July 1, 2018 San Francisco Marriott Marquis San Francisco, CA. Headache J Head Face Pain. 2018;58(Suppl.2):68–69.
Metadata
Title
Evaluation of Patients with Insufficient Efficacy and/or Tolerability to Triptans for the Acute Treatment of Migraine: A Systematic Literature Review
Authors
Elizabeth Leroux
Andrew Buchanan
Louise Lombard
Li Shen Loo
Daisy Bridge
Ben Rousseau
Natasha Hopwood
Brandy R. Matthews
Uwe Reuter
Publication date
01-12-2020
Publisher
Springer Healthcare
Published in
Advances in Therapy / Issue 12/2020
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-020-01494-9

Other articles of this Issue 12/2020

Advances in Therapy 12/2020 Go to the issue

Original Research

Adherence to the EAU Guideline Recommendations for Local Tumor Treatment in Penile Cancer: Results of the European PROspective Penile Cancer Study Group Survey (E-PROPS)

Original Research

A Retrospective Cohort Study to Investigate the Incidence of Cachexia During Chemotherapy in Patients with Colorectal Cancer

Original Research

Clinical Characteristics of a Non-Alcoholic Fatty Liver Disease Population Across the Fibrosis Spectrum Measured by Magnetic Resonance Elastography: Analysis of Screening Data

Review

A Narrative Review of the Patient Journey Through the Lens of Non-communicable Diseases in Low- and Middle-Income Countries

Original Research

A Retrospective Observational Analysis of Overall Survival with Sipuleucel-T in Medicare Beneficiaries Treated for Advanced Prostate Cancer

Original Research

Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Standard of Care in Latin America for Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Propensity Score Matching Analysis

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits